KRAS and neoplasm: Mutations in TP53, PIK3CA, EGFR, and KRAS were often accompanied by a high TMB status in the tumor, while the special cases were the TP53 mutant group in uterine corpus endometrial carcinoma and the EGFR mutant group in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).